News | July 14, 2009

Study Looks at Long-term Outcomes of DES Use in Patients With RI

July 14, 2009 – Despite the fact that drug-eluting stent (DES) implantation reduces restenosis and the need for target vessel revascularization (TVR), these stents appear to be associated with unfavorable long-term outcomes in patients with moderate or severe renal insufficiency (RI), according to a study in this week’s issue of the International Journal of Cardiology, Volume 136, Issue 1, pages 72-79, July 2009.

Researchers at Rui Jin Hospital and Jiao Tong University School of Medicine in Shanghai, China, sought to examine the impact of moderate or severe RI on long-term clinical outcomes after successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation. They found all-cause mortality and major adverse cardiac events were prospectively determined for 1,174 patients after successful PCI with drug-eluting stent implantation. Based on estimated creatinine clearance (CrCl) levels, long-term outcomes were compared between patients with CrCl

Patients in the RI group were older, mainly female and had lower body weights and hemoglobin than those in the control group. The RI group also had fewer cigarette smokers. During follow-up (averaged 19.2 months) after successful PCI, all-cause death (8.3 percent vs. 1.5 percent), cardiac death (5.7 percent vs. 1.1 percent) and occurrence of nonfatal myocardial infarction (2.2 percent vs. 0.4 percent) were significantly higher, but the rate of TVR was lower (5.7 percent vs. 9.6 percent) in the RI group than in the control group. Multivariate analysis revealed that a CrCl

For more information: www.internationaljournalofcardiology.com

Related Content

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init